Tag - VRDN

Developments

Viridian reports details of SC VRDN-003 Phase 3 clinical program for patients with TED

Viridian Therapeutics (NASDAQ:VRDN) announced details of its plans to initiate two Phase 3 clinical trials of its subcutaneous VRDN-003 product candidate for patients with active and chronic moderate-to-severe thyroid...

June 11, 2024

Markets

SVB Leerink starts Viridian Therapeutics at OP, PT $32

SVB Leerink launched coverage of Viridian Therapeutics (NASDAQ:VRDN) with an “outperform” rating and $32 price target. The stock closed at $19 on Nov. 17. Viridian is a clinical-stage biotech company focused on the...

November 18, 2021

Markets

Ladenburg starts Viridian Therapeutics at buy; PT $40

Ladenburg Thalmann launched coverage of Viridian Therapeutics (NASDAQ:VRDN) with a “buy” rating and $40 price target. The stock closed at $21.78 on Jan. 22. Viridian’s lead asset, VRDN-001, is an anti-IGF-1R monoclonal...

January 25, 2021

Tag - VRDN

Viridian reports details of SC VRDN-003 Phase 3 clinical program for patients with TED

SVB Leerink starts Viridian Therapeutics at OP, PT $32

Ladenburg starts Viridian Therapeutics at buy; PT $40

General

More